Expert Perspectives on Diagnosis and Treatment of OAB: A Roundtable Discussion : Episode 3

EP. 2: The Diagnostic Process of OAB and Initial Patient-Clinician Conversations

July 19, 2023

By Benjamin M. Brucker, MD
Eman A. Elkadry, MD

Video

Experts begin their panel discussion on OAB by describing the typical diagnostic process and initial conversations that they have with patients suspected of having the condition.

Please see full Prescribing Information for onabotulinumtoxinA, including Boxed Warning.

EP: 1.In-Clinic Educational Resource on the OAB Treatment Pathway

EP: 2.EP. 1: An Introduction of the Speakers

Now Viewing

EP: 3.EP. 2: The Diagnostic Process of OAB and Initial Patient-Clinician Conversations

EP: 4.Ep. 3: The Typical Patient with OAB and Common Signs and Symptoms

EP: 5.EP. 4: The Role of Urodynamic Testing in OAB Evaluation

EP: 6.EP. 5: OAB Treatment: Available Strategies and Rationale for Use

EP: 7.EP. 6: Factors Informing Selection of Pharmacologic Treatment for OAB

EP: 8.Ep. 7: Defining Pharmacologic Treatment Failure in Patients with OAB and Subsequent Treatment Strategies

EP: 9.EP. 8: Patient-Clinician Conversations Regarding Initial Pharmacologic Treatment for OAB

EP: 10.EP. 9: Treatment Goals and Educational Resources for Patients on Initial Pharmacologic Therapy for OAB

EP: 11.EP. 10: Third-Line OAB Therapies and Patient-Centered Decision-Making

EP: 12.EP. 11: Setting Treatment Expectations for Patients with OAB Receiving Third-Line Therapies

EP: 13.EP. 12: OAB Patient Monitoring and Followup Considerations in the Third-Line Treatment Setting

EP: 14.EP. 13: Re-Treatment and Scheduling with OnabotulinumtoxinA

EP: 15.EP. 14: SNM and PTNS for OAB: Device Management and Followup

EP: 16.EP. 15: Subsequent Treatment Considerations for Patients with Unsatisfactory Responses to Third-Line Therapy for OAB

This content is intended for US/PR Healthcare Professionals.

The Medical Affairs department of AbbVie Inc. is the sole author and copyright owner of this presentation and has paid Urology Times to host this presentation. AbbVie is solely responsible for all written and oral content within this presentation. © 2023 AbbVie Inc. All rights reserved.

Related Content

Emerging multiplex UTI testing drives Medicare costs amid increased utilization

Celeste Krewson, Assistant Editor

November 27th 2024

Article

A recent study found a sharp rise in Medicare claims for multiplex urinary tract infection testing from 2016 to 2023, underscoring a significant financial impact and the need for further research into its clinical benefits.

How Individually Identifying More HPV Types Enables Better Patient Management and More Precise Care

September 29th 2023

Podcast

Listen

Online misinformation about UTIs and ASB reported

Celeste Krewson, Assistant Editor

November 21st 2024

Article

A study highlights the poor quality of online information about urinary tract infections and asymptomatic bacteriuria, raising concerns about inaccurate diagnoses, overtreatment, and antibiotic resistance.

The Importance of Including Hemoglobinopathies as a Part of Carrier Screening Panels

September 15th 2023

Podcast

Listen

Female sexual dysfunction education found lacking

Celeste Krewson, Assistant Editor

October 16th 2024

Article

In a recent study, significantly more urology websites contained information about male sexual dysfunction when compared to the availability of female sexual dysfunction information on ob-gyn websites.

Self-diagnosing vaginismus found accurate vs health care provider diagnosis

Celeste Krewson, Assistant Editor

October 15th 2024

Article

In a recent study presented at the 25th Annual Fall Scientific Meeting of SMSNA, similar diagnosing success was reported between self-diagnosis and diagnosis from a health care provider for vaginismus.